NCT03077685 - Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Interventions

DRUG

NanoPac®

Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.

Trial Locations (4)

46845

Parkview Cancer Institute, Fort Wayne

77030

Baylor College of Medicine, Houston

79905

Texas Tech University Health Sciences Center, El Paso

90048

Cedars-Sinai Medical Center, Los Angeles